# 1. Financial Performance ## A. Key Figures * **Revenue (Consolidated):** **₹391.7 Cr** Q4 (+17.4%) · **₹1,353 Cr** FY26 (+31.7%) * **EBITDA:** **₹43.9 Cr** Q4 (11.2% Margin) · **₹148.5 Cr** FY26 (+5.4%, 11% Margin) * **PAT:** **₹20.1 Cr** Q4 (5.1% Margin) · **₹56.6 Cr** FY26 * **Segment Revenue (FY26):** **Glass Lined Products:** **₹676 Cr** · **Filtration & Drying:** **+50.9% growth** · **Heat Transfer:** **+64.6% growth** ## B. Margin & Profitability * **Acquisition Drag:** Consolidated profitability was weighed down by transition costs and a combined **₹30.9 Cr** EBITDA/PAT loss from the newly acquired Omeras business in Germany. * **Exceptional Impacts:** Full-year results include **₹6.7 Cr** in one-time charges related to acquisition costs and New Labour Code adjustments. * **Path to Breakeven:** Omeras is nearing operational breakeven, with management projecting double-digit margins next fiscal year upon reaching a quarterly revenue run-rate of **₹45 Cr to ₹50 Cr**. * **Realization Headwinds:** Despite higher production volumes, revenue growth was tempered by a decrease in value per equipment and subdued margins compared to the 2021-2022 peak. ## C. Capital Allocation * **Shareholder Returns:** The Board recommended a **55% dividend** for FY26, signaling confidence in sustainable cash flow generation and long-term fundamentals. * **Balance Sheet Optimization:** Management is actively divesting nonviable segments and focusing on working capital efficiency to enhance financial flexibility. ## D. Segment Performance * **Filtration & Drying Momentum:** Remained a primary growth engine for the year, driven by leadership in process automation and robust demand for advanced solutions. * **Strategic Acquisitions:** Omeras (acquired for **₹27 Cr**) contributed **₹89 Cr** in partial-year revenue; its order book has already doubled to approximately **₹79 Cr**. * **International Footprint:** Thaletec remains a significant contributor, representing **24%** of the Glass Lined segment with annual revenue of **€3.4 Crore** and steady double-digit EBIT margins. * **Heat Transfer Resilience:** While Q4 saw a slight revenue dip, the segment achieved massive full-year expansion supported by oil and gas sector orders and a growing international pipeline. --- # 2. Order Book & Demand ## A. Key Figures * **Consolidated Order Book:** **₹681.6 Cr** As of March 31, 2026 * **Omeras Order Book:** **₹78 Cr** (~2x growth vs. Dec '25) ## B. Order Visibility * **Robust Growth Runway:** The consolidated backlog provides strong revenue visibility for FY27, supported by a pipeline expected to sustain momentum for the next **two years**. * **Omeras Scaling:** Significant expansion in the Omeras business unit establishes a stable foundation for profitable plant operations in the near term. ## C. Sectoral Demand * **Pharma & API Leadership:** Growth is primarily anchored by the Indian pharma, API, and CDMO sectors, which are driving the highest demand for filtration, drying, and glass-lined equipment. * **Mixed Chemical Recovery:** Specialty chemicals are showing gradual improvement, while agrochemicals remain subdued despite a selective uptick in inquiries. * **Strategic Diversification:** Through Kinam, the company is entering the **oil and gas and petrochemical** sectors; however, management maintains conservative projections as a new entrant in these verticals. * **Global Supply Chain Shifts:** Demand is bolstered by global supply chain diversification and a preference for reliable engineering partners in high-performance segments. ## D. Pricing Power & Operations * **Cost Pass-Through:** Demonstrated pricing power by successfully passing on increased operational costs and rising gas prices to customers, mitigating geopolitical and energy-related headwinds. * **Utilization Ramp-up:** Anticipated increase in Indian glass-lined equipment utilization is being fueled by the API pharmaceutical recovery and CDMO demand. --- # 3. Manufacturing & Capacity ## A. Key Figures * **GLE Capacity Utilization (India):** **~75%** Current (Target: **80%**) * **Production Volume (GLE India):** **+30% to 40%** Equipment units dispatched over 4-year period ## B. Utilization Rates & Outlook * **Approaching Peak Capacity:** Glass-lined equipment (GLE) utilization is nearing management’s optimal threshold, supported by a specialized focus on **Pharma API and Specialty Chemical** sectors. * **Heat Exchanger Momentum:** Segment utilization has exceeded previous guidance; management projects **15% to 20%** growth over two years, with capacity expansion evaluations slated for next year. * **Volume vs. Value Divergence:** While GLE revenue has remained range-bound between **INR 200–250 Cr**, actual shop floor productivity and unit throughput have seen robust double-digit growth. ## C. Capex & Strategic Expansion * **New Facility Timeline:** India-based capex is on track for commercial operations by **FY25 year-end**, with meaningful revenue contributions expected to materialize in **FY27**. * **Market & Product Strategy:** Initial production at the new facility will prioritize tanks for **wastewater, semiconductors, and biogas**; the site will serve domestic demand and act as a hub for the **Middle East**. --- # 4. M&A & Strategic Initiatives ## A. Key Figures * **Product Mix:** **20%** contribution of Thaletec products to Indian GLE portfolio * **M&A Track Record:** **4** successful acquisitions integrated to date (Swiss Glascoat, Kinam, Thaletec, Omeras) ## B. Integration Progress * **Strategic Consolidation:** Completed the acquisition of Omeras GmbH and the NCLT-approved amalgamation of Kinam Enterprise, significantly bolstering heat transfer equipment capabilities. * **Omeras Turnaround Strategy:** Management is prioritizing execution quality and selective order booking over rapid scaling; while currently a drag on consolidated margins, profitability is expected as the new management team stabilizes operations. * **Institutionalized Integration:** A dedicated internal team is leveraging experience from multiple past acquisitions to manage organizational complexity and ensure smooth transitions for new entities. ## C. Acquisition Synergies * **Thaletec Performance:** Post-acquisition, the unit has achieved robust double-digit growth and margins by expanding customer engagement across the U.S. and Europe. * **Omeras Synergy Potential:** Value creation is centered on significant customer overlap in the international tank business and cross-border technology exchange in glass-lined manufacturing. ## D. Technology Differentiation & Global Platform * **Niche Market Focus:** The M&A strategy remains disciplined, targeting businesses with high entry barriers and differentiated technologies to avoid "me-too" product segments. * **Portfolio Evolution:** High-end product integration is already yielding results, with specialized international ranges now making a **meaningful impact** on the domestic product mix. * **Global Process Platform:** The long-term vision is to leverage established hubs in Europe, the Middle East, and the U.S. to build a scalable, technology-led global equipment platform. --- # 5. Geography & Market Mix ## A. Key Figures * **Historical India GLE Range:** **₹200 Cr – ₹250 Cr** (Since 2022) * **Thaletec EBITDA Margin:** **Low double-digit** (Stable) ## B. India Operations * **Recovery & Utilization:** The Glass Lined Equipment (GLE) segment saw a late-year recovery, fueled by improved execution and higher capacity utilization within pharma and specialty chemicals. * **Sector Diversification:** Management is pivoting heat exchanger growth toward **petrochemical and oil & gas** penetration while defending its leadership in core chemical and pharma verticals. * **Revenue Momentum:** Domestic GLE performance reached a new high-water mark, breaking out of the stagnant range maintained since 2022. ## C. European Footprint * **Thaletec Turnaround:** Despite stagnant top-line growth following a soft Q3, a robust order book supports a positive outlook for the German operations. * **Geographic Scaling:** Footprint expansion is underway beyond the traditional **DACH region** (Germany, Austria, Switzerland) to capture broader pan-European demand. * **Omeras Strategy:** Expansion for Omeras will follow a two-step phase, first scaling across Europe (beyond Italy/Germany) before a planned entry into the **D. S. market**. * **Demand Drivers:** European growth is expected to be anchored by the architectural and tanks segments, though Omeras margins may lag double digits in the near term. ## D. Export & Global Expansion * **Strategic Phasing:** Future heat exchanger expansion is prioritized in two stages: first targeting the **Middle East**, followed by the **United States**. * **Middle East Potential:** Identified as a high-growth hub for heat exchangers; the company has already established a **local sales team** to capture regional demand once geopolitical volatility eases. --- # 6. Risks & External Factors ## A. Geopolitical Impact * **Geopolitical Headwinds:** External global instability emerging since **February 2026** has created a challenging business environment, tempering broader sectoral recovery. * **Resilient Pharma Demand:** Despite macro volatility, the pharmaceutical and API sectors maintain a positive trend and stable operational outlook. ## B. Sectoral Deferrals * **Capex Delays:** Ongoing geopolitical tensions have prompted CDMO and agrochemical clients to defer critical investment decisions. --- # 7. Guidance & Outlook ## A. Key Figures * **Consolidated Revenue Target:** **₹2,000 Cr** within two years (vs. **~₹1,250 Cr** current base) * Kinam (Heat Transfer) Growth: 15% to 20% CAGR over next two years * **Omeras Revenue Target:** **>₹200 Cr** for the current year * EBITDA Margin (Core): 13.5% adjusted (ex-Omeras) · 16% target in next 2 years ## B. Revenue & Profitability Targets * **Aggressive Top-line Scaling:** Management anticipates significant consolidated growth over the medium term, bolstered by the integration of the Omeras acquisition. * **Operational Turnaround:** Focus remains on stabilizing Omeras in the current fiscal, supported by a robust order book and pipeline to drive a sustainable recovery. * **Margin Optimization:** Profitability strategy for **FY27** centers on asset utilization and efficiency to bridge the gap between current core performance and the mid-teen consolidated target. * **Geographic Margin Mix:** Consolidated profitability expectations account for the structural difference between the high-margin Indian operations (**15%+**) and the lower-margin German business. ## C. Growth Strategy * **Sector Tailwinds:** The company is positioned to capture value from global pharmaceutical CAPEX as project execution cycles commence over the medium term. * **Portfolio Diversification:** Growth is underpinned by the core pharmaceutical API business, supplemented by new forays into **biogas storage**, **architectural businesses**, and **storage systems**.